Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)

Inclusion Criteria: * patients undergoing revascularization for significant coronary artery disease * age range 21-85 years Exclusion Criteria: * non-STEMI, STEMI * cancer * renal failure with creatinine\>3.0mg/dl * liver cirrhosis * lymphoproliferative disorder * pregnancy * thrombocytopenia\<150'000 * coagulopathy (INR\>1.5) * abnormal liver function tests * illicit drug use * history of statin intolerance * history of rhabdomyolysis * planned use of Glycoprotein IIb/IIIa inhibitors during PCI * current therapy with atorvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin